Last reviewed · How we verify
NCT00505245
New Assessment System in Measuring Symptom Distress in Cancer Patients
trial testing Interview in Caregiver in 6,500 participants. Currently enrolling.
30 April 2031
Quick facts
| Lead sponsor | M.D. Anderson Cancer Center |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 6,500 |
| Start date | 13 April 1999 |
| Primary completion | 30 April 2031 |
| Estimated completion | 30 April 2031 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Interview
- Quality-of-Life Assessment
- Questionnaire Administration
Conditions studied
- Caregiver — all drugs for Caregiver →
- Health Care Provider — all drugs for Health Care Provider →
- Malignant Neoplasm — all drugs for Malignant Neoplasm →
- Physician — all drugs for Physician →
Sponsor
M.D. Anderson Cancer Center — full company profile →
Who can join
18 and older, any sex, with Caregiver or Health Care Provider. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This trial studies how well a new assessment system (MDASI or other MD Anderson-developed PRO instrument) works in measuring symptoms and the impact on quality of life in cancer patients. Development of a new assessment system may provide more information about the common symptoms that may occur in patients due to cancer and its treatment and how the symptoms impact quality of life.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Current Progress of CAR-NK Therapy in Cancer Treatment.
Pang Z, Wang Z, Li F, Feng C, et al · · 2022 · cited 38× · PMID 36077853 · DOI 10.3390/cancers14174318 -
Clinical application and prospect of immune checkpoint inhibitors for CAR-NK cell in tumor immunotherapy.
Yang K, Zhao Y, Sun G, Zhang X, et al · · 2022 · cited 25× · PMID 36741400 · DOI 10.3389/fimmu.2022.1081546 -
Measuring quality of life in acute myeloid leukemia: limitations and future directions.
Buckley SA, Lee SJ, Walter RB. · · 2016 · cited 9× · PMID 27389467 · DOI 10.1080/17474086.2016.1211006
Verify or expand the search:
- PubMed search for NCT00505245
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Interview
Trials testing the same drug.
- NCT07377006 — Decision Support Tool to Enhance Germline Genetic Testing for Patients With Prostate Cancer · NA · not yet recruiting
- NCT07226102 — Virtual Mental Health Intervention to Address Fear of Progression for Women With High Risk or Stage III-IV Gynecologic o · NA · withdrawn
- NCT07225855 — Geriatric Assessment and Management for Older Adults Undergoing Chemotherapy and Radiation Therapy for Head and Neck Can · NA · not yet recruiting
- NCT07282444 — A New Way to Share Radiation Therapy Plans Between Doctors, CORRECT Trial · NA · not yet recruiting
- NCT07490860 — A Restorative Justice-Based Lung Cancer Screening Decision-Making Support Intervention Tailored for Black Individuals to · NA · not yet recruiting
Other recruiting trials for Caregiver
Currently open trials in the same condition.
- NCT07225179 — mHealth for Early Psychosis Caregivers in Statewide Program Outreach · NA · recruiting
- NCT07239869 — A Robot-assisted Tailored Activity Programme for People With Dementia and Their Caregivers · Phase 1 · recruiting
- NCT06989086 — FearLess in NeuroOncology · NA · recruiting
- NCT06944262 — Assessment of Cancer-related Post-traumatic Stress in Patients and Caregivers in the Year Following Diagnosis, and Ident · recruiting
- NCT06631144 — A Spanish-language Caregiver-Enabled Care Program · NA · active not recruiting
Other M.D. Anderson Cancer Center trials
Trials by the same sponsor.
- NCT07053020 — A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukem · Phase 1, PHASE2 · not yet recruiting
- NCT07052994 — A Phase Ia/Ib Trial of Revumenib Combined With Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin (GO) in Frontline and · Phase 1 · not yet recruiting
- NCT07137481 — Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Che · Phase 2 · not yet recruiting
- NCT07162480 — Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid Cystic Ca · Phase 2 · not yet recruiting
- NCT07076498 — Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standar · Phase 1 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT00505245 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by M.D. Anderson Cancer Center
- Last refreshed: 21 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00505245.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing